Welcome to Aprilla Health, your trusted resource for all things health and wellness. Our mission is to empower you with up-to-date, evidence-based information and practical advice to enhance your health and improve your quality of life. Explore our extensive library of articles, interactive tools, and videos covering a wide range of topics including nutrition, exercise, mental health, and disease prevention. Whether you’re looking to make healthier lifestyle choices, manage a specific health condition, or just stay informed, Aprilla Health is here to support you every step of the way. Connect with our community of experts and like-minded individuals who are dedicated to a healthier, happier you!

Internet-Based Cognitive Behavioral Therapy Can Improve Depression and Insomnia, According to New Study by Hebrew University Researchers

June 5, 2024 — Significant improvements in insomnia symptoms and depression, over time, can be achieved using internet-based cognitive behavioral therapy (ICBT), according to a new study by Hebrew University of Jerusalem researchers. ICBT has been developed and tested for a range of conditions including both psychiatric and somatic health problems and also transdiagnostic problems like loneliness and poor self-esteem. 

The new study in Psychotherapy Research led by Dr. Dina Zalaznik from the Hebrew University Department of Psychology highlights the critical role of interpersonal factors in ICBT. Cognitive Behavioral Therapy aims to help you identify and challenge unhelpful thoughts and to learn practical self-help strategies. These strategies are designed to bring about immediate positive changes in your quality of life. These findings advance the understanding of depression treatment through internet interventions and therapy’s broader benefits.

The study focused on two crucial aspects: the therapeutic alliance and attachment styles. Study participants, consisting of thirty-nine mostly female participants (59%) with an average age of 38 years, were recruited through ads for a free trial and underwent screening, including online surveys and a phone interview. The internet-based cognitive behavioral therapy program consisted of six modules covering psychoeducation, cognitive work, behavioral activation, challenging thoughts, optional cognitive behavioral therapy for insomnia, and relapse prevention. 

 Read more…

FDA Approves First Treatment for Patients with Fatty Liver Disease

March 27,2024 - The US Food & Drug Administration (FDA) recently approved Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring, to be used along with exercise and diet.

Today, the U.S. Food and Drug Administration approved Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), to be used along with diet and exercise. 

“Previously, patients with NASH who also have notable liver scarring did not have a medication that could directly address their liver damage,” said Nikolay Nikolov, M.D., acting director of the Office of Immunology and Inflammation in the FDA’s Center for Drug Evaluation and Research. “Today’s approval of Rezdiffra will, for the first time, provide a treatment option for these patients, in addition to diet and exercise.” 

NASH is a result of the progression of nonalcoholic fatty liver disease where liver inflammation, over time, can lead to liver scarring and liver dysfunction. NASH is often associated with other health problems such as high blood pressure and type 2 diabetes. By at least one estimate, approximately 6-8 million people in the U.S. have NASH with moderate to advanced liver scarring, with that number expected to increase. Rezdiffra is a partial activator of a thyroid hormone receptor; activation of this receptor by Rezdiffra in the liver reduces liver fat accumulation. 

Scroll to Top